-
Nilutamide
- indication:For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2).
- pharmacologypharmacology:
- mechanism: Nilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. This blockade of androgen receptors may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis.
- toxicity: Symptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting.
- absorprion: Rapidly and completely absorbed, yielding high and persistent plasma concentrations.
- halflife: 38.0-59.1 hours
- roouteelimination: Nilutamide is extensively metabolized andless than 2% of the drug is excreted unchanged in urine after 5 days. Fecal elimination is negligible, ranging from 1.4% to 7% of the dose after 4 to 5 days.
- volumedistribution:
- clearance: